Sangamo Therapeutics, Inc. (LON: 0R1D)

Market Cap	194.82M
Revenue (ttm)	39.01M
Net Income (ttm)	-100.60M
Shares Out	n/a
EPS (ttm)	-0.52
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	45,242
Average Volume	177,983
Open	1.090
Previous Close	1.135
Day's Range	1.090 - 1.150
52-Week Range	0.290 - 2.111
Beta	n/a
RSI	35.45
Earnings Date	Mar 5, 2025

About Sangamo Therapeutics

Sangamo Therapeutics, Inc., a clinical-stage genomic medicine company, focuses on translating science into medicines that transform the lives of patients and families afflicted with serious diseases in the United States. The company’s clinical-stage product candidates are ST-920, a gene therapy product candidate, which is in Phase 1/2 clinical study for the treatment of Fabry disease; TX200, a chimeric antigen receptor engineered regulatory T cell (CAR-Treg) therapy product candidate that is in Phase 1/2 clinical study for the prevention of imm...

• Industry: Medical - Pharmaceuticals
• Sector: Healthcare
• Founded: 1995
• Employees: 405
• Stock Exchange: London Stock Exchange
• Ticker Symbol: 0R1D

Financial Performance

In 2023, Sangamo Therapeutics's revenue was $176.23 million, an increase of 58.34% compared to the previous year's $111.30 million. Losses were -$257.83 million, 34.1% more than in 2022.

Financial numbers in USD